Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome.
Familial
HNPCC
Screening
Stomach
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
14
02
2019
revised:
03
07
2019
accepted:
09
07
2019
pubmed:
19
7
2019
medline:
19
8
2021
entrez:
19
7
2019
Statut:
ppublish
Résumé
Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer. We aimed to identify clinical factors associated with gastric cancer in carriers of germline variants causing Lynch syndrome. We collected data from 52,758 consecutive individuals tested for genetic variants associated with Lynch syndrome from June 2006 through July 2013 at a commercial laboratory. We obtained clinical and demographic data, as well as information on personal and family histories of cancer (first- and second-degree relatives) from forms completed by ordering providers. We performed multivariate logistic regression to identify clinical factors associated with gastric cancer in carriers of mutations that cause Lynch syndrome (pathogenic mutations). After we excluded individuals with missing clinical data (n = 1664) or with multiple pathogenic mutations (n = 8), we analyzed data from 51,086 individuals. Of these, 3828 persons carried pathogenic mutations (1346 with mutations in MLH1, 1639 with mutations in MSH2, 670 with mutations in MSH6, 145 with mutations in PMS2, and 28 with mutations in EPCAM). Of the 3828 carriers of pathogenic mutations, 41 (1.1%) had a previous gastric cancer and 350 (9.1%) had 1 or more first- or second-degree relatives with gastric cancer. In multivariate analysis, male sex (odds ratio [OR], 2.82; 95% CI, 1.48-5.38), older age (OR, 2.07 per 10 years; 95% CI, 1.64-2.61), mutations in MLH1 (OR, 6.53; 95% CI, 1.50-28.42) or MSH2 (OR, 5.23 compared to mutations in MSH6, PMS2, or EPCAM; 95% CI, 1.21-22.71), and number of first-degree relatives with gastric cancer (OR, 2.52; 95% CI, 1.42-4.45), but not second-degree relatives (OR, 1.12; 95% CI, 0.40-3.18) were independently associated with gastric cancer among carriers of pathogenic mutations. In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and number of first-degree relatives with gastric cancer. These findings suggest that personalized, risk-stratified approaches to gastric cancer surveillance may be appropriate for individuals with Lynch syndrome-associated mutations.
Sections du résumé
BACKGROUND & AIMS
Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer. We aimed to identify clinical factors associated with gastric cancer in carriers of germline variants causing Lynch syndrome.
METHODS
We collected data from 52,758 consecutive individuals tested for genetic variants associated with Lynch syndrome from June 2006 through July 2013 at a commercial laboratory. We obtained clinical and demographic data, as well as information on personal and family histories of cancer (first- and second-degree relatives) from forms completed by ordering providers. We performed multivariate logistic regression to identify clinical factors associated with gastric cancer in carriers of mutations that cause Lynch syndrome (pathogenic mutations).
RESULTS
After we excluded individuals with missing clinical data (n = 1664) or with multiple pathogenic mutations (n = 8), we analyzed data from 51,086 individuals. Of these, 3828 persons carried pathogenic mutations (1346 with mutations in MLH1, 1639 with mutations in MSH2, 670 with mutations in MSH6, 145 with mutations in PMS2, and 28 with mutations in EPCAM). Of the 3828 carriers of pathogenic mutations, 41 (1.1%) had a previous gastric cancer and 350 (9.1%) had 1 or more first- or second-degree relatives with gastric cancer. In multivariate analysis, male sex (odds ratio [OR], 2.82; 95% CI, 1.48-5.38), older age (OR, 2.07 per 10 years; 95% CI, 1.64-2.61), mutations in MLH1 (OR, 6.53; 95% CI, 1.50-28.42) or MSH2 (OR, 5.23 compared to mutations in MSH6, PMS2, or EPCAM; 95% CI, 1.21-22.71), and number of first-degree relatives with gastric cancer (OR, 2.52; 95% CI, 1.42-4.45), but not second-degree relatives (OR, 1.12; 95% CI, 0.40-3.18) were independently associated with gastric cancer among carriers of pathogenic mutations.
CONCLUSIONS
In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and number of first-degree relatives with gastric cancer. These findings suggest that personalized, risk-stratified approaches to gastric cancer surveillance may be appropriate for individuals with Lynch syndrome-associated mutations.
Identifiants
pubmed: 31319185
pii: S1542-3565(19)30745-1
doi: 10.1016/j.cgh.2019.07.012
pmc: PMC6960373
mid: NIHMS1534704
pii:
doi:
Substances chimiques
MutL Protein Homolog 1
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
830-837.e1Subventions
Organisme : NCI NIH HHS
ID : K07 CA151769
Pays : United States
Organisme : NCI NIH HHS
ID : K24 CA113433
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132829
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
J Clin Oncol. 2015 Jan 10;33(2):209-17
pubmed: 25452455
J Clin Oncol. 2018 Oct 10;36(29):2961-2968
pubmed: 30161022
Int J Colorectal Dis. 2016 Mar;31(3):693-7
pubmed: 26847620
JCO Clin Cancer Inform. 2018 Dec;2:1-11
pubmed: 30652589
N Engl J Med. 2006 Jan 19;354(3):261-9
pubmed: 16421367
Gastroenterology. 2010 Feb;138(2):487-92
pubmed: 19900449
J Clin Oncol. 2017 Jul 1;35(19):2165-2172
pubmed: 28489507
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Ann Oncol. 2013 Oct;24 Suppl 6:vi73-80
pubmed: 23813931
Cancer. 1971 Jun;27(6):1505-11
pubmed: 5088221
Scand J Gastroenterol. 2002 May;37(5):574-7
pubmed: 12059060
Gastroenterology. 2014 Aug;147(2):502-26
pubmed: 25043945
Cancer. 2017 Dec 15;123 Suppl 24:4994-5013
pubmed: 29205310
J Clin Oncol. 2012 Dec 10;30(35):4409-15
pubmed: 23091106
Gut. 2013 Jun;62(6):812-23
pubmed: 23408351
Gastroenterology. 2000 May;118(5):829-34
pubmed: 10784581
Eur J Cancer. 2018 Nov;104:91-103
pubmed: 30342310
Turk J Gastroenterol. 2017 Nov;28(6):434-438
pubmed: 29086710
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):404-412
pubmed: 27799157
JAMA Oncol. 2018 Jun 1;4(6):876-879
pubmed: 29710084
J Clin Oncol. 2012 Mar 20;30(9):958-64
pubmed: 22331944
Lancet. 2011 Dec 17;378(9809):2081-7
pubmed: 22036019
Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263
pubmed: 25645574
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682